284 related articles for article (PubMed ID: 8004664)
41. [Efffect of plasminogen activator inhibitor-1 and endothelin-1 on the atherosclerosis in the maintenance hemodialysis patients].
Ouyang L; Peng Y; Wu G; Xu X; He Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 May; 38(5):458-67. PubMed ID: 23719522
[TBL] [Abstract][Full Text] [Related]
42. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
43. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
44. Increased basal levels of free plasminogen activator activity found in human aqueous humor.
Wang Y; Taylor DM; Smalley DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3561-6. PubMed ID: 8056534
[TBL] [Abstract][Full Text] [Related]
45. [Post-mortem concentration of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) in the vitreous body of the human eye].
Przygońska J; Kotschy M; Sliwka K; Kulwas A
Klin Oczna; 1996 Mar; 98(3):205-8. PubMed ID: 9019590
[TBL] [Abstract][Full Text] [Related]
46. Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
Erdem Y; Haznedaroglu IC; Celik I; Yalcin AU; Yasavul U; Turgan C; Caglar S
Nephrol Dial Transplant; 1996 Jul; 11(7):1299-305. PubMed ID: 8672026
[TBL] [Abstract][Full Text] [Related]
47. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Opatrný K; Opatrná S; Vít L; Opatrný K
Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033
[TBL] [Abstract][Full Text] [Related]
48. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
[TBL] [Abstract][Full Text] [Related]
49. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis.
Sabovic M; Salobir B; Preloznik Zupan I; Bratina P; Bojec V; Buturovic Ponikvar J
Pathophysiol Haemost Thromb; 2005; 34(6):274-8. PubMed ID: 16772739
[TBL] [Abstract][Full Text] [Related]
50. Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders.
Opatrný K; Zemanová P; Mares J; Vít L; Opatrná S; Sefrna F; Hejda V; Tomsů M; Eiselt J; Massry SG
Am J Nephrol; 2002; 22(5-6):429-36. PubMed ID: 12381940
[TBL] [Abstract][Full Text] [Related]
51. Fibrinolysis in chronic renal failure, dialysis and renal transplantation.
Opatrný K; Zemanová P; Opatrná S; Vít L
Ann Transplant; 2002; 7(1):34-43. PubMed ID: 12221902
[TBL] [Abstract][Full Text] [Related]
52. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
53. Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age.
Yamamoto K; Loskutoff DJ; Saito H
Semin Thromb Hemost; 1998; 24(3):261-8. PubMed ID: 9701458
[TBL] [Abstract][Full Text] [Related]
54. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Choudhury NA; Pietraszek MH; Hachiya T; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 May; 66(4):321-9. PubMed ID: 1412199
[TBL] [Abstract][Full Text] [Related]
55. Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.
Avellone G; Di Garbo V; Cordova R; Raneli G; De Simone R; Bompiani GD
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):429-33. PubMed ID: 8329569
[TBL] [Abstract][Full Text] [Related]
56. Fibrinolytic response to venous occlusion for 10 and 20 minutes in healthy subjects and in patients with deep vein thrombosis.
Petäjä J
Thromb Res; 1989 Oct; 56(2):251-63. PubMed ID: 2515609
[TBL] [Abstract][Full Text] [Related]
57. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction.
Gray RP; Patterson DL; Yudkin JS
Arterioscler Thromb; 1993 Mar; 13(3):415-20. PubMed ID: 8443145
[TBL] [Abstract][Full Text] [Related]
58. A study of the fibrinolytic response in healthy men and women following a brief exposure to venous occlusion.
Lacroix KA; Bean C; Box L; Wagner K
Thromb Res; 1996 Jan; 81(1):133-43. PubMed ID: 8747528
[TBL] [Abstract][Full Text] [Related]
59. [A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease].
Chen ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Jun; 21(3):163-4, 188. PubMed ID: 8243232
[TBL] [Abstract][Full Text] [Related]
60. The effect of chronic allograft rejection on plasma regulators of fibrinolysis.
Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z
Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
